Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The question they paid 500,000 or almost 1 million in legal fees and all the shareholder got was bankruptcy all assets sold an still owe $385,000.? What was the point of chapter 11. other than to close the books in these stock scheme. and somebody made millions on it and got off clean.
if this company still had the LENZ and owns the patents it they can raise additional shareholder money and raise 10 million but not with 44 million in liabilities. whether they are disputed or not.lawsuits are considere debt or liabilities no investors would touch a company with lawsuits.
The company has no money or cash and still owes $385,000? who will pay the $385,000..And the dip loan. why would Durrant give the company a 1 million dollar loan for. the risk is repaymen of the 1 million loan if management embezzles or has to repay creditors. why give the loan for. As for Lenz, hgenq doesn't own any assets. it's shell company and all creditors claims should have been discharged. wasted enough time of the two judges and 3 months peoples time in a bogus fake bankruptcy filing. Only loser were the 180 million they raised in 2021 and shareholders. who lost buying the shares when it was trading above $3. and think it would get FDA approval.
The company still owes $27,000 of the pathogen's bogus $27 million lawsuit claim which was. the company should countersue pathogen for $5 million for making fake creditor claims okay! and same with the Chime 7.3 million initially it was 4.3 million but increased to 2 million because it feels like it creditor claim and $3 million fake lawsuit. It was these 44 million fake creditor lawsuits why the company had to file bankruptcy as no investors would invest in a company that is in legal ligitation or that was the plan to bankrupt the company and makes shares worthless. skewing the investors who bought at average cost of $3.
Feb 29 2024 humanigen creditor released. The company now after all assets sold and 44 million creditor claim reduced to 385,000
Chime and pathogen, over 44 million creditor claim discharged. The question why did humanigen wire $350,000 to some university of Zurich bank account for? The account could be fake account in swiss bank which has no identification needed to open a swiss bank account.or fake documents use to open a swiss bank account. There is only 3 employees and one board that is paid $10,000 for his time. So the company spent half a million dollars in legal fees and still owes $385,000? all the creditor claims except a salaries and legal fees should be paid. What relationship or business does the university of zurich does humanigen with that entity, there is no vendor invoice or work completed documents.
The data from the LIVE-AIR patient population would be of sufficient volume for the FDA to make a regulatory decision. Trial size was established in consultation between the FDA and management.
The NIH ACTIV-5 trial tested late stage patients, including patients who had, or were on, IMV. The FDA even included patients on ECMO, whose outcomes were not to be factored into the trial results.
No new trial is required for an EUA. We should be able to extract ACTIV-5 results for their patients who were in ordinal scale 5, and use those results as an adjunct to the LIVE-AIR trial results, if necessary. The ACTIV-5 patients in ordinal scales 6 and 7 were too progressed in disease severity, and were not included in LIVE-AIR. We also have safety and efficacy data from lenz on the PREACH-M study, which may soon win approval in Australia, and all of this data could be included in a resubmission of our EUA application. I think our OS is already higher than management wants, and I doubt they will reverse split, even at 1:5. There will be no need to do so, anyway, after the loaned shares are recalled, and we could even see a forward split, which I hope we don't, even f it would be temporary.
That’s not entirely true . What happens to the cash which is lying there given as part of APA.
Agreed , the live AIR trial met the end point . However at that time, the data was deemed not sufficient to get a EUA. That’s why the data from the NIH trial was needed to get to that end point . However as many noted the primary end point was not met . Now we can all agree or disagree , but any new path way for an EUA or a BLA would require a new trial with hundreds of millions of dollars. Something the company cannot raise . As a shareholder I would not support any such irresponsible decisions . Also we no longer own lenz . This point is moot unless a reverse merger happens . And I don’t see a pathway for it yet . Even if there is one , existing shareholders would find their holdings diluted to a large extent . Maybe a 5:1 or a 10:1 . With that kind of dilution , they will find themselves completely sidelined .
Welcome to the room, SorcererGuru44, and thank you for your considerate post.
Folks keep your post on Topic! No Personal, Religious, or Political Post Please!!!
Good news for Invivyd (IVVD), and signals Regulatory stance on mAbs.
"March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc...today announced interim exploratory COVID-19 clinical event data for VYD222, an investigational, monoclonal antibody (mAb) in development for the pre-exposure prophylaxis of COVID-19."
https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-interim-exploratory-data-vyd222-ongoing-canopy
Invivyd is defining 'pre-exposure' differently than I am accustomed to seeing. They are not saying their mAb is for covid-naive patients. They're saying just the opposite.
"Exploratory data such as provided in today’s update are important for broad reflection as they represent some of the first data from a clinical trial conducted with a monoclonal antibody in a population that has acquired prior immune exposure from either vaccination or natural infection. By contrast, studies of prior authorized COVID-19 PrEP mAbs largely relied on participants required by protocol to be naïve to vaccination or prior infection." I guess the mass vaccination assault expanded the allowable definition of 'pre-exposure prophylaxis.'
In addition to the above Release Details, Invivyd also issued Release Details, which mentions the EUA.
https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-fda-authorization-emergency-use-pemgardatm
I'm actually encouraged by this.
"A PREP Act declaration is specifically for the purpose of providing immunity from liability"
https://aspr.hhs.gov/legal/PREPact/Pages/default.aspx
It only makes sense to have an alternative, traditional vaccine, available to meet healthcare demands, in the event that mRNA vaccine manufacturers withdraw from the market, when PREP Act protection expires. The only traditional vaccine approved for use in the US is the Novavax vaccine. If the safety and efficacy of that vaccine proves to be enhanced by Humanigen's patented methodology, using lenzilumab, then the company needs to be prepared to meet that demand.
Not only is the subject germane, the issue is critical. We cannot let a highly lethal virus attach to receptor cells, and if they do, we need to combat the effects of that infection vigorously and effectively, using lenzilumab, in both processes. Lenzilumab showed outstanding results when administered early. The LIVE-AIR trial met the primary endpoint, and those results have been peer-reviewed by both Lancet and Thorax. The company has a history of treatment data for the product, even preceding Covid.
I guess the company either sabotage the clinical trials or didn't pay the FDA some cash in paper brown bags. Even a weight loss drug that has severe side effects get FDA approval.
https://www.msn.com/en-us/health/other/dozens-sue-saying-ozempic-other-weight-loss-and-diabetes-drugs-cause-harmful-side-effects/ar-BB1kiyr0
Weight loss drugs are too harmful to even use but somehow the drug was approved by FDA? The risk is not worth the cure like losing weight. which is not even an illness that needs a cure. These drugs just cause a patient to get sick so they lose their apetitite and FDA approves as their is big market for weight loss industry. obesity is not disease and can be cured with natural remedy like stop eating and starve. by not over eating.
the gov't is the 3 million legal settlement. but the gov't won't waste anymore time in collecting money from an 'entity' with no assets and nothing
HGENQ as a legal 'entity' has no debt, no assets, and no employees. an gov't has til July 1,2024 to object bankruptcy filing. march 20 was the final objection date for any creditor claims. so as result all the 40 million creditor claims are now discharged and invalid. as of today.
lots of delusional investors and is pissed off and don't want to believe truth. and accept the reality. hgenq no longers owns any LENZ patent and has no assets. what don't you understand? only asset is some promissory note that it may get payment for possible payment IF LENZ gets 1 billion in sales from Taran. Now, if Taran goes bankrupt, that promissory not longer applies. and yo have t sue Taran to get any payment but if hgenq is shell company it has no money to file any legal claims for breach of promissory note. the hgenq shell company can delisted and cease to exist too for failing to file SEC reports or not pay annual incorporation fees.
The trading is indicate a b.s. A.I is running this stock.
A.I. is the market maker for all stocks now. Human traders don't have an edge anymore
These A.I. Front run human orders. manipulate the bid and ask. on zero volume. making fake volume and fake trades.
8 sell orders and trades by A.I. someone messing around. and it's not human
daily range is
.000001 - .0001 ?
hgenq is not the only stock that is investment scam. the scheme wast to sell tonnes of equities on pipe dreams that FDA would approve the drug since it is corvid and stage 3. now they steal the assets for free and make people who own the shares or bought in pipe speculation about FDA approvals and fake contracts..when the plan was to go bankrupt and sabotage FDA clinical trials. this is the game that hundreds of companies do..why go public if your business is that profitable. and sell shares.
hgenq is the fate of 99% of all equities in the OTC all eventually become worthless and go bankrupt. why you think warren Buffet would not invest in it? or has no stock analyst from reputable firms like morgan stanley or goldman sachs.? no pension would want to touch these companies from 100 foot pole. you have management that wants to fail and go bankrupt. that was the plan, you had no chance. if you did management could have fake the clinical trials and made the FDA deny the patent. known self sabotaging the company to go bankrupt.
Thank You for your concern over our worthless expert market company. You made a lot of great points except for one. That is after bankruptcy we are debt free and a clean shell with a very attractive share structure. I'm sure a private company would like to take over the shell to go public. Once current the owner decides bring HGENQ current and file with the OTC this will be worth a lot more money. It will also come back off the expert market.
What I don't understand is why all of your concern with this worthless shell? Is there some serious short going on here? Maybe you are trying to convince current HGENQ share holder Speculators to sell you .0001 shares? I'm holding 4 million shares that you guys sold me in December for .00027 average. I got 1 million up for sale at .40 cents if you need to cover. The rest I won't let go until much higher prices. I will either go bust with these or make a fortune. Really not worried as I trade other stocks. This is just a nice lotto for me.
Like the fake creditors who think a bankrupt company with no assets and no cash will pay the 30 million cash they think they are owed.
These creditors are not entitled to anything with their 40 million fake creditor claims and fake $3 million settlement.
These lawsuits is reason the company declared bankruptcy. now they get nothing in putting the claims and wasted millions in legal fees
thinking they get any of the claims or any of the $3 million settlement.. the court trial like watching WWF wrestling a fake show.
delusional investors won't accept reality.
The bankruptcy force to sell all assets of any value to Taran Theureuptic who now own the patents.
What don't you understand? People keep talking about short squeeze and LENZ etc talking non-sense
Lawsuits are waste courts' time
Two judges had to waste time hearing two fake court hearings.
The company has less employees than a 7-11 convenient store. and in the financial statements its assets are worthless.
The shares are more like an option with an expiry date than shares or equity as of today.
That is the reality of the ticker but people who thought they were investing some molecule still wont accept the reality their investment is worth 99,999% less than
they paid for it. if you bought the shares at .15/share and think the shares would be worth at least a buck, well as of now there is no chance it will ever be worth $1 without FDA approval since LENZ doesn't own the LENZ patent even LENZ is approved it will never be worth $5 again.
the company only has only 3 full time employees, that is how small this company is.
And management of this company is not investable too. management is a liability in this company.
Companies like humanigen don't have any positive cashflow from business operations. it's like charity, all expenses is funded by shareholders injecting cash into to fund research and the CEO $400,000/year salary. The business has no revenues. only source of cash or revenue was investors who bought the shares, and that initial cash has dried up and due to the $3 million lawsuit and $1 million in legal fees, there is no cash left. and reason for the bankruptcy, Investors see lawsuits a debt. that 40 million liability is same as bank loan debt. and reason nobody will invest in shares of the company with that much debt or liability. and on the book the IP assets are 'worthless' so why invest.
The company managmenet deliberattely choos to not file SEC reports and get delisted. and be at the expert market. I've seen bankrupt companies have qoutes. as long as the company file SEC reports. The company has not filed any quarterly reports, which is the minimum to get listed in any exchange. it doesn't matter if company is bankrupty, have no assets, no employees. when trading in the pinksheets unlike nasdaq and NYSE listings. To be listed in the nasdaq, you need assets to be min. $100 million. in your balance sheet and share price min. of $1.. OTC markets there is no listing requirments other than filing the quarterly SEC reports. even if you have no financial statements. They just to know the company exist.
There is no reason the OTC markets not public level 2 or not quotes. the stock can get delisted too if company doesn't file SEC reports.
The stock is now tradinng at the OTC or pinksheet which is less regulated that a flea market or craigslist. and facebook marketplace
look at the data. If the exchange can b.s. like this with fake documents saying the short position and authorized shares is 250 million shares. outsanding shares is 119 million shares. who are these idiots talking about recalling 125 million shares is that a naked short. Did some market maker short 250 million shares. Naked shorting can only be done by broker dealers market makers, it's a privillege only professionals can get. like citadel not retail accounts.
The One guy who owns the company controls over 90% of the trading shares and is also the market maker. in the otc it shows 38,000 shares still short at .0001 anyone still short is a market maker or broker dealer. no retail would short a stock or still holding a short position when stock is .00001 for months. so the expert market is b.s. too. like this market.
The company is now shell company with no liabilities, no assets, and no employees. What don't you dreamers don't understand. As for the shareholders, you are not shareholders since management would not even answer your phone calls, You own the stock ticker on the portfolio but you don't own the company. You have no say on management decisions.
HGENQ doesn't own the patents to LENZ anymore, it's sold it for nothing.
Creditors get nothing. nor does the any of the claimants who think they should get .047/shares. with the $3 million dollar payout settlement that was agreed to pay before the chapter 11 filing. The company doesn't have $3 million to pay and if does pay, the law firm would deny claims or not pay as HGENQ if paying is paying to the law firm who filed the lawsuit not to individual investors who think they were entitled to anything and paid $500 or something to application fee for the payment. Probaably wasted your time scanning documents an sending your information to the law company asking for proof you bought the shares between may 16 2020 and july 13 2022. You know how hard to confirm you bought it? It impossible or very time consuming to verify who bought it between may 16 2020 and july 13 2022. That can only be confirmed by broker electronically, paper can be fake documents showing your bought it.
If you're not a shareholder, please go away from here and take your time.
I agree with both of you. .....and I have lost more here than 90% of anyone who has ever posted on this board. I don't need this "newbie" to describe anything to me. I also question purpose of said posts.
I don’t get it either, this person has been doing it several times with several various screen names here and another message board.
Not going to argue the validity of his posting, just seems a strange way of doing it?
First, thank you for your information. but why go to the extent of creating an account just to refute in such detail? Is it a sense of public duty?
the $3 million dollar settlment doesn't make logical sense either. the shareholders bought shares between $20 to $4 were to get .047/share as a settlement. its peanuts if they loss $100,000 with 20,000 shares and average cost was $5 but only get $940 settlement after pay legal fees they get $500?
and they sold. their shares too. How the legal settlement got $3 million value is the question.
Only the broker can verify and confirm that a particular shareholder bought shares from may 16- july 2022. and it cost money to confirm that. How can they confirm any claim that the paper documents are real and not fake? The easiest way was via the transfer agent who has all the records and no need to ask people to send in claims for payment . The brokers charges $300 to remove a delisted stock from your portfolio and only takes a few minutes to do. The transfer agent has all the info or shareholder list in a particular time period. you had to be buyer of the shares to qualify. and that is another problem to pay. if you bought less than $100 worth of shares, it cost more to print a check and send it to your home address. The transfer agent has no record of who bought the shares they just have record of who owned the shares so this $3 settlement is rediculous saying only people who bought the shares are entiteled and max is only $3 million they can pay out
The 3 million dollar settlement is void and discharged after chapter 11 isn't it. and is bogus lawsuit who claim to have loss money due to management mislead. There were way more shareholder losses than 3 million. More likely the firm gets the 3 million but don't pay a dime to the claimants because who can the confirm people sending the proofs were real shareholders who bough the shares from may 16 2020- july 12 2022. For legal business you are saying only people who bought the shares on that date is qualified? This is wall street, shareholders are taking the risk and know the risk, very few companies pay their shareholders for this kind of lawsuit, it's like shareholder suing the company for compensation, but the company has no money to pay and goes bankrupt, shareholders loses on his investment and gets no payment.
Yesterday, was the last day or March 20, that any creditors can object to the discharge, no creditor objected so all their claims or the 40 million is no void and invalid. The gov't has or any gov't has til july 1 to object to the chapter 11 as that is highly unlikely any gov't would waste any more time in this chapter 11 filing. Essentially, the companies has no liabilities. and no assets. other than claim like an option on Taran who bought the assets. Taran didn't even have to pay anything or agreed to the schmuck insurance. As for the .047/share payment with the $3 million dollar settlement, that was before the chapter 11 filing. How anyone can prove they bought owned the shares is questionable as that information is only available in the brokers records. The law firm who filed the lawsuit if they do get any payment from HGENQ can just keep the $3 million.
After chapter 11 HGENQ is now a shell company with no assets, no liabilities, and no employees.
LENZ and all intellectual property was sold for nothing
Any talk of 'recalling' shorted shares is non-sense. and delusional as all the shorts covered their short positions. Either your doing a pump and dump scheme in a shell company, why even talk about 'short squeeze'. There is no short squeeze.
Now if the shares were to got o. 35/share it won't be short squeeze or even pump and dump, it would be cause FDA approves LENZ for manufacturing and commercialization. The licensing few is only a few millions. and that is payable to Taran who now owns the IP for LENZ or any biotech patent that humanigen had.
so are you claiming that july is the last incoming and then they can reverse after that?
regardless of whether or not they can do that why would anyone be perilously short with the history of this company. surely nobody could discount what they might try.
on another note since taran is private, lets say they get a voucher for x dollars. ( i doubt it)
do they have to report it or would it be reported by default?
jay if you are correct and lenzilumab has all this unbelievable potential , what makes you think the market didn’t realize it long ago like you
Please take further notice that on March 19, 2024, the Court entered an order (the “Bar Date
Order”)2
establishing: (i) April 22, 2024 at 5:00 p.m. (prevailing Eastern Time) (the “General
Bar Date”) as the last date and time for each person or entity to file a Proof of Claim in this
Chapter 11 Case, including claims arising under section 503(b)(9) of the Bankruptcy Code;
(ii) April 22, 2024 at 5:00 p.m. (prevailing Eastern Time) (the “Administrative Claims Bar
Date”) as the deadline for each person or entity that asserts a request for payment of administrative
expense claims (collectively, the “Administrative Claims”) arising between the Petition Date and
February 20, 2024 (the “Administrative Claims Deadline”) to file a request for payment of such
Administrative Claims; and (iii) and July 1, 2024 at 5:00 p.m. (prevailing Eastern Time)
(the “Governmental Bar Date”) as the date by which all governmental units holding claims
(whether secured, unsecured priority, or unsecured non-priority) that arose (or are deemed to have
arisen) before the Petition Date must file Proofs of Claim, including claims for unpaid taxes,
whether such claims arose from prepetition tax periods or prepetition transactions to the Debtor
were a party https://document.epiq11.com/document/getdocumentbycode?docId=4309765&projectCode=HUM&source=DM
If they would have recalled the shares before BK, they would have had to pay back the 40 million they owed. The share call back is speculative but what I don;t understand is why not declare liquidation? Why keep the share structure in place
You could be absolutely right, dlog.
Because I believe in the huge potential of lenz to effectively treat, and then to possibly prevent, a huge number of indications, and also because I believe in the good character of our management, I have made it my objective to try to understand what this management team is doing to get their lenz into the market. And I have shared my conclusions and opinions here.
Yes, there would have been benefit with an earlier recall of the loaned shares. It would have amounted to a blip on the radar. Even if it staved off the bankruptcy, the momentum would not have been sustained, without news leading to our ability to generate a revenue stream.
In the US, and in the UK, we're looking for regulatory approval for lenz to treat covid. That would cause the FDA and the MHRA to destroy the markets for Pfizer and Moderna, who provide the vast majority of the regulators' operating funds. It would also threaten the value of the intellectual property OWNED BY THE REGULATORS in the Pfizer and Moderna mRNA vaccines. Regulators would be slicing their own financial throats by approving Humanigen's lenzilumab, and the Novavax vaccine that uses lenz as an enhancement.
We have to capitalize on the IND authorization by having partners use lenz under IND for their vaccine and CAR-T products. We also need to exploit our opportunity for regulatory approval of lenz from Australia, to treat CMML. It's almost "game-over" for the attempts to deny our revenue stream. We will prevail. It would be an absolute catastrophe to use mRNA technology to fight a virus that could have 100% mortality, such as the Pangolin Coronavirus.
We need to see regulatory approval of lenz, which is most likely to first come from Australia. And the flood gates will then be open.
And that's when management can recall their loaned shares to the fullest monetary advantage.
seems to me if what you believe is true, the “share recall” could have solved all the company problems.
there would have been no need for any BK
its just more fantasy just like novavax is a fantasy.
Followers
|
327
|
Posters
|
|
Posts (Today)
|
7
|
Posts (Total)
|
43258
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |